Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greater than 90% after haploidentical donor HCT in children and young adults with SCD. Primary Objective: \- To assess the GVHD-free and rejection free survival (GRFS) after haploidentical donor HCT in children and young adults with SCD. Secondary Objectives: * Assess the overall survival (OS) and disease-free survival (DFS) after haploidentical donor HCT for SCD. * Estimate incidence and severity of acute and chronic GVHD after haploidentical donor HCT for SCD. * Assess the neutrophil and platelet engraftment kinetics after haploidentical donor HCT for SCD.

NCT Number	NCT07616154
Lead Sponsor	St. Jude Children's Research Hospital
Conditions	Sickle Cell Disease
Enrollment	45 participants
Start Date	2026-09
Primary Completion	2034-09 (estimated)
Study Completion	2035-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-23